Patents by Inventor Lisa Ooi

Lisa Ooi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TREATMENT AND/OR PREVENTION OF A VIRAL INFECTION
    Publication number: 20230355602
    Abstract: A method of treating or preventing a viral infection comprising administering a DHODH inhibitor to a patient in need thereof. Also provided is the use of the DHODH inhibitor for the treatment or prevention of a viral infection, alone or in combination with another therapy, and formulations or compositions comprising the DHODH inhibitor suitable for treating or preventing viral infections.
    Type: Application
    Filed: August 30, 2021
    Publication date: November 9, 2023
    Inventors: Bertil LINDMARK, Mark MCHALE, Ann Gee Lisa OOI, Qihui SEET, Eng Eong OOI
  • Cancer therapy
    Patent number: 11382903
    Abstract: A method of treating haematological cancer with a therapy comprising a DHODH inhibitor. Also provided is a combination therapy comprising a pan-HER inhibitor and a DHODH inhibitor for treating a haematological cancer.
    Type: Grant
    Filed: October 8, 2018
    Date of Patent: July 12, 2022
    Assignee: Aslan Pharmaceuticals Pte. Ltd.
    Inventors: Bertil Lindmark, Ann Gee Lisa Ooi, Mark Thomas McHale
  • Cancer therapy
    Patent number: 11311548
    Abstract: A method of treating haematological cancer with a therapy comprising a DHODH inhibitor. Also provided is a combination therapy comprising a pan-HER inhibitor and a DHODH inhibitor for treating a haematological cancer.
    Type: Grant
    Filed: January 18, 2019
    Date of Patent: April 26, 2022
    Assignee: Aslan Pharmaceuticals Pte. Ltd.
    Inventors: Bertil Lindmark, Ann Gee Lisa Ooi, Mark Thomas McHale
  • Combination therapy comprising Varlitinib and an anticancer agent
    Patent number: 10849899
    Abstract: In one aspect the present disclosure provides a method of sensitizing a cancer patient to chemotherapy by administering a combination therapy comprising; a) a therapeutically effective amount of a compound of formula (I) an enantiomer thereof or a pharmaceutically acceptable salts of any one of the same, and b) a chemotherapeutic agent or a combination of chemotherapeutic agents.
    Type: Grant
    Filed: July 11, 2019
    Date of Patent: December 1, 2020
    Assignee: ASLAN Pharmaceuticals PTE LTD
    Inventors: Bertil Lindmark, Lisa Ooi
  • Varlitinib for use in the treatment of resistant or refractory cancer
    Patent number: 10682353
    Abstract: The present disclosure provides a method of treating a patient with refractory or resistant cancer by administering a therapeutically effective amount of a compound of formula (I), such as Varlitinib, or an enantiomer thereof or a pharmaceutically acceptable salt of any one of the same. Also provided is a compound of formula (I) for use in the treatment of resistant or refractory cancer and use of a compound of formula (I) for the manufacture of a medicament for the treatment of resistant or refractory cancer.
    Type: Grant
    Filed: September 5, 2016
    Date of Patent: June 16, 2020
    Assignee: ASLAN Pharmaceuticals PTE LTD
    Inventors: Bertil Lindmark, Lisa Ooi
  • METHOD OF TREATMENT USING IL-13R ANTIBODY
    Publication number: 20200165347
    Abstract: The present disclosure provides a method of treating cutaneous T cell lymphoma (CTCL), in particular mycosis fungoides and/or Sézary syndrome, comprising administering a therapeutically effective amount of an antagonist antibody or binding fragment thereof specific to the IL-13 receptor to a patient in need thereof.
    Type: Application
    Filed: June 29, 2018
    Publication date: May 28, 2020
    Inventors: Bertil Lindmark, Ann Gee Lisa Ooi
  • Combination Therapy Comprising Varlitinib and an Anticancer Agent
    Publication number: 20200009144
    Abstract: In one aspect the present disclosure provides a method of sensitizing a cancer patient to chemotherapy by administering a combination therapy comprising; a) a therapeutically effective amount of a compound of formula (I) an enantiomer thereof or a pharmaceutically acceptable salts of any one of the same, and b) a chemotherapeutic agent or a combination of chemotherapeutic agents
    Type: Application
    Filed: July 11, 2019
    Publication date: January 9, 2020
    Inventors: Bertil Lindmark, Lisa Ooi
  • Combination therapy comprising varlitinib and an anticancer agent
    Patent number: 10357494
    Abstract: In one aspect the present disclosure provides a method of sensitizing a cancer patient to chemotherapy by administering a combination therapy comprising; a) a therapeutically effective amount of a compound of formula (I) an enantiomer thereof or a pharmaceutically acceptable salts of any one of the same, and b) a chemotherapeutic agent or a combination of chemotherapeutic agents.
    Type: Grant
    Filed: September 5, 2016
    Date of Patent: July 23, 2019
    Assignee: ASLAN Pharmaceuticals PTE LTD
    Inventors: Bertil Lindmark, Lisa Ooi
  • CANCER THERAPY
    Publication number: 20190151326
    Abstract: A method of treating haematological cancer with a therapy comprising a DHODH inhibitor. Also provided is a combination therapy comprising a pan-HER inhibitor and a DHODH inhibitor for treating a haematological cancer.
    Type: Application
    Filed: January 18, 2019
    Publication date: May 23, 2019
    Applicant: Aslan Pharmaceuticals Pte. Ltd.
    Inventors: Bertil Lindmark, Ann Gee Lisa Ooi
  • Method of Treating Liver Cancer
    Publication number: 20190134034
    Abstract: A method of treating liver cancer, such as hepatocellular carcinoma, by administering a compound of formula (I), such as Varlitinib, or an enantiomer thereof, or a pharmaceutically acceptable salt thereof. Also provided is a compound of formula (I) for use in the treatment of liver cancer and use of a compound of formula (I) in the manufacture of a medicament for the treatment of liver cancer.
    Type: Application
    Filed: April 21, 2017
    Publication date: May 9, 2019
    Applicant: ASLAN Pharmaceuticals Pte. Ltd.
    Inventors: Lisa Ooi, Bertil Lindmark
  • Treatment of Biliary Duct Cancer
    Publication number: 20190117655
    Abstract: The present disclosure provides a method of treating a biliary duct cancer, such as cholangiocarcinoma, by administering a therapeutically effective amount of a compound of formula (I), in particular Varlitinib, an enantiomer thereof or a pharmaceutically acceptable salt of any one of the same.
    Type: Application
    Filed: September 18, 2018
    Publication date: April 25, 2019
    Applicant: ASLAN Pharmaceuticals PTE LTD
    Inventors: Bertil Lindmark, Mark Thomas McHale, Lisa Ooi
  • CANCER THERAPY
    Publication number: 20190038610
    Abstract: A method of treating haematological cancer with a therapy comprising a DHODH inhibitor. Also provided is a combination therapy comprising a pan-HER inhibitor and a DHODH inhibitor for treating a haematological cancer.
    Type: Application
    Filed: October 8, 2018
    Publication date: February 7, 2019
    Applicant: Aslan Pharmaceuticals Pte. Ltd.
    Inventors: Bertil Lindmark, Ann Gee Lisa Ooi
  • Treatment of Biliary Duct Cancer
    Publication number: 20180353510
    Abstract: The present disclosure provides a method of treating a biliary duct cancer, such as cholangiocarcinoma, by administering a therapeutically effective amount of a compound of formula (I), in particular Varlitinib, an enantiomer thereof or a pharmaceutically acceptable salt of any one of the same.
    Type: Application
    Filed: September 5, 2016
    Publication date: December 13, 2018
    Inventors: Bertil Lindmark, Mark Thomas McHale, Lisa Ooi
  • A Combination Therapy Comprising Varlitinib and an Anticancer Agent
    Publication number: 20180256578
    Abstract: In one aspect the present disclosure provides a method of sensitizing a cancer patient to chemotherapy by administering a combination therapy comprising; a) a therapeutically effective amount of a compound of formula (I) an enantiomer thereof or a pharmaceutically acceptable salts of any one of the same, and b) a chemotherapeutic agent or a combination of chemotherapeutic agents.
    Type: Application
    Filed: September 5, 2016
    Publication date: September 13, 2018
    Inventors: Bertil Lindmark, Lisa Ooi
  • Varlitinib for Use in the Treatment of Resistant or Refractory Cancer
    Publication number: 20180243302
    Abstract: The present disclosure provides a method of treating a patient with refractory or resistant cancer by administering a therapeutically effective amount of a compound of formula (I), such as Varlitinib, or an enantiomer thereof or a pharmaceutically acceptable salt of any one of the same. Also provided is a compound of formula (I) for use in the treatment of resistant or refractory cancer and use of a compound of formula (I) for the manufacture of a medicament for the treatment of resistant or refractory cancer.
    Type: Application
    Filed: September 5, 2016
    Publication date: August 30, 2018
    Inventors: Bertil Lindmark, Lisa Ooi